Although BRAF is frequently mutated across multiple cancer types, its clinical utility as a prognostic biomarker has remained inconsistent in clinical practice, likely due to additional events modulating BRAF signaling pathways. This inconsistency has driven our investigation into the broader landscape of BRAF signaling and the development of a robust molecular signature to assess BRAF-driven oncogenic activity. To achieve this, we introduced BRAF25, a transcriptional signature designed to effectively capture BRAF oncogenic activity. Our findings reveal that 25.6% of TCGA colorectal cancer (CRC) tumors exhibit BRAF pathway activation, even in 19.4% of BRAF wild-type (WT) cases, suggesting alternative mechanisms driving pathway activation. The BRAF-active subtype, termed BAG-3 (BRAF Activity Group-3), demonstrated reduced responsiveness to chemotherapy and anti-BRAF therapy. Notably, BRAF25 subtyping addresses the limitations of using BRAF mutation alone to predict patient survival. We experimentally screened and validated DUSP6 as a sensitizing target for anti-BRAF therapy, enhancing BRAF inhibitor efficacy in CRC. Furthermore, pan-cancer analyses implicate the BRAF25 signature in poor prognosis across diverse BRAF-driven malignancies. In conclusion, stratifying patients by transcriptional BRAF oncogenic activity, instead of relying solely on BRAF mutation status, provides a more precise approach to guide clinical decision-making and improve therapeutic outcomes.

Objective: To investigate the clinical features, molecular subtypes, and factors influencing metastasis in patients with breast cancer chest wall metastasis. Methods: We collected the clinical data of patients who developed isolated chest wall metastasis following radical surgery for breast cancer. The molecular subtypes of the primary lesions and secondary biopsy lesions in patients with chest wall metastasis were analyzed and summarized. The disease-free survival (DFS) after breast cancer surgery and its influencing factors were also documented. Results: Of the 99 cases of isolated chest wall recurrence included in our study, DFS varied from 1 to 264 months, with a median DFS of 36 months. The 3-year disease-free survival rate was 44.6%, while the 5-year rate was 24.2%. Molecular subtype changes occurred in a total of 28 cases before and after metastasis, accounting for 34% of the cases. COX multivariate analysis revealed that pathological type, surgical staging, postoperative expression status of ER (estrogen receptor), PR (progesterone receptor), Ki-67, HER-2 (human epidermal growth factor receptor-2), and the receipt of adjuvant chemotherapy after surgery were independent factors affecting chest wall recurrence and metastasis. Conclusion: Local recurrence after breast cancer surgery increases the risk of distant metastasis. Identifying high-risk factors for recurrence enables the tailoring of individualized comprehensive treatment plans based on the patient's condition, thus reducing the risk of local recurrence and improving survival outcomes.

The present study aimed to investigate the predictive value of pretreatment fibrinogen (FIB) levels in patients with cancer who received immunotherapy as a second-line treatment. A total of 61 patients with stage III-IV cancer were included. The cut-off value of FIB for predicting overall survival (OS) was determined by receiver operating characteristic curve analysis. The prognostic value of pretreatment FIB on progression-free survival (PFS) and OS was determined by univariate and multivariate analyses. Based on a cut-off point of 3.47 g/l, patients were divided into low pretreatment FIB (<3.47 g/l) and high pretreatment FIB (≥3.47 g/l) groups. A high pretreatment FIB level was more common in older patients (P=0.03). Kaplan-Meier analysis showed that patients with high pretreatment FIB levels had shorter PFS and OS times than patients with low FIB levels (P<0.05). In multivariate analysis, pretreatment FIB was an independent prognostic factor for OS [hazard ratio (HR), 6.06; 95% CI, 2.01-18.28; P<0.01] and OS from the initiation of second-line treatment (HR, 3.69; 95% CI, 1.28-10.63; P=0.02). Overall, FIB is associated with survival outcome in patients with cancer who are administered immunotherapy as a second-line treatment.

Immune checkpoint inhibitors (ICIs) have been an encouraging treatment method in non-small cell lung cancer (NSCLC). However, bone and liver metastases are considered to restrain immunotherapy efficacy. Since serum alkaline phosphatase (ALP) is associated with bone and liver metastases, it was investigated whether serum ALP could be a novel biomarker to predict the efficacy of ICIs treatment. In the present study, 143 patients with NSCLC receiving ICIs treatment were retrospectively analyzed. The objective response rate (ORR) was compared between the ALP high and low groups, bone metastasis and non-bone metastasis groups, and liver metastasis or non-liver metastasis groups. The associations between clinical characteristics, including ALP level, bone or liver metastasis and median progression-free survival (mPFS) time were analyzed by univariate and multivariate Cox regression analysis. It was found that bone metastasis was associated with a lower ORR (24 vs. 43%; P<0.05) and shorter mPFS (10.2 vs. 17.3 months; P=0.010) in patients with NSCLC receiving ICIs. Liver metastasis was associated with lower ORR (22 vs. 38%; P<0.05), but not with mPFS (P=0.119). The ALP level was higher in patients with bone or liver metastasis than in those without (119.6 or 103.6 vs. 83.3 U/l, respectively; P<0.05). Higher ALP levels were also associated with bone or liver metastasis, lower ORR (20 vs. 39%; P<0.05) and shorter mPFS (8.5 vs. 15.4 months; P=0.009). Cox regression analysis demonstrated that ALP was an independent prognostic indicator of mPFS (hazard ratio, 1.856; 95% confidence interval, 1.030-3.343; P=0.040). In conclusion, pretreatment levels of serum ALP might be a predictive indicator of clinical outcome in patients with NSCLC after ICIs treatment.

INTRODUCTION:Gastric cancer is the most fifth common tumor worldwide. Human epidermal growth factor receptor 2 (HER2) overexpression is associated with poor prognosis and clinical characteristics in gastric cancer. Nevertheless, the biology of HER2-low expression has not reported in gastric cancer.MATERIALS AND METHODS:A total of 157 patients with early-stage gastric cancer were retrospectively analyzed. The associations between HER-2 low expression and clinical characteristics were analyzed by Chi-square test. And the prognostic value of HER-2 low expression and clinical characteristics in disease-free survival (DFS) and overall survival (OS) were analyzed by univariate and multivariate Cox regression analysis.RESULTS:Of 157 patients with early-stage gastric cancer, 31.8% had HER2-low tumors and 50.3% had HER2-negative tumors. HER2-low expression was associated with age, histological differentiation, tumor location and Ki-67 index. However, HER2-low expression was not associated with DFS or OS in early-stage gastric cancer.CONCLUSION:HER2-low expression might result in distinct biology, but it was not an independent prognostic factor of DFS or OS in early-stage gastric cancer.

PURPOSE:The relationship between high blood glucose and colorectal cancer (CRC) has been studied, but the role of postoperative fasting blood glucose (FBG) in patients with a prior normal FBG has never been addressed. METHODS:A total of 120 CRC patients staged I-III were enrolled, and the prognostic value of postoperative FBG for disease-free survival (DFS) was determined by Kaplan-Meier analysis. Univariate and multivariate analyses were conducted to test other clinicopathological parameters, including preoperative hemoglobin (HGB) and the neutrophil-lymphocyte ratio (NLR). RESULTS:By a cut-off point of 5.11 mmol/L, 51 and 69 patients were divided into low postoperative FBG (<5.11 mmol/L) and high postoperative FBG (≥5.11 mmol/L) groups, respectively. A high postoperative FBG was more common in older age (P = 0.01), left-located tumor (P = 0.02), smaller tumor diameter (P = 0.01), node negative involvement (P = 0.01), lesser positive lymph nodes (P = 0.02), and high preoperative HGB (P = 0.01). Further, high postoperative FBG patients displayed a significantly better DFS than low postoperative FBG patients (48.80 ± 22.12 months vs. 40.06 ± 24.36 months, P = 0.04), but it was less likely to be an independent prognostic factor. CONCLUSIONS:Postoperative FBG plays a temporal prognostic role for patients with stage I-III CRC with a prior normal FBG, but it is not an independent prognostic factor.

Background: Gastric cancer (GC) is the most lethal tumor of gastrointestinal tract worldwide. Despite advances in various therapies, the prognosis of GC remains poor. Moreover, only a small fraction of GC patients benefit from immunotherapy. Therefore, it is urgent to deeply understand the molecular characteristics and immunophenotype of GC. Methods: We analyzed the gene expression profile of GSE118916 from GEO database, including the mRNA expression profiles of 15 pairs of GC tumor and adjacent non-tumor tissues. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using the online website DAVID. And then the survival prediction values of the top 10 up-regulated genes were analyzed using Kaplan–Meier plotter database. Finally, the immune cells infiltration was analyzed using CIBERSORT online tool. Results: A total of 1156 DEGs were identified, including 633 up-regulated genes and 523 down-regulated genes. The up-regulated genes were mainly enriched in cell adhesion, proliferation, migration and inflammation response. In addition, the up-regulated genes were significantly enriched in acid metabolism, complement and coagulation cascades, cell adhesion and p53 signaling pathway, which were all significant in tumor progression, relapse and metastasis. In addition, the up-regulated genes CTSL and PIEZO1 were associated with poor prognosis in GC patients. Moreover, a unique immune-suppressive microenvironment was identified in GC tissues. Conclusions: CTSL and PIEZO1 might be potential biomarkers and therapeutic targets in GC patients.

Objective To investigate the difference in texture features on diffusion weighted imaging (DWI) images between breast benign and malignant tumors.Methods Patients including 56 with mass-like breast cancer, 16 with breast fibroadenoma, and 4 with intraductal papilloma of breast treated in the Hainan Hospital of Chinese PLA General Hospital were retrospectively enrolled in this study, and allocated to the benign group (20 patients) and the malignant group (56 patients) according to the post-surgically pathological results. Texture analysis was performed on axial DWI images, and five characteristic parameters including Angular Second Moment (ASM), Contrast, Correlation, Inverse Difference Moment (IDM), and Entropy were calculated. Independent sample t-test and Mann-Whitney U test were performed for intergroup comparison. Regression model was established by using Binary Logistic regression analysis, and receiver operating characteristic curve (ROC) analysis was carried out to evaluate the diagnostic efficiency.Results The texture features ASM, Contrast, Correlation and Entropy showed significant differences between the benign and malignant breast tumor groups (PASM=0.014, Pcontrast=0.019, Pcorrelation=0.010, Pentropy=0.007). The area under the ROC curve was 0.685, 0.681, 0.754, and 0.683 respectively for the positive texture variables mentioned above, and that for the combined variables (ASM, Contrast, and Entropy) was 0.802 in the model of Logistic regression. Binary Logistic regression analysis demonstrated that ASM, Contrast and Entropy were considered as the specific imaging variables for the differential diagnosis of breast benign and malignant tumors.Conclusions The texture analysis of DWI may be a simple and effective tool in the differential diagnosis between breast benign and malignant tumors.

目的 探讨术前血小板计数和肿瘤最大径比(platelet count and maximum tumor size ratio,PTR)对非转移性胃癌患者患者3年无疾病生存期(disease free survival,DFS)的预测价值.方法 收集我院自2012年12月-2018年6月经根治术后病理确诊的非转移性胃腺癌患者75例,收集患者术前血小板计数和性别、年龄等临床参数,结合肿瘤大小进一步统计分析.结果 PTR对判断患者3年DFS存在一定价值(AUC=0.35,95％CI=0.21-0.48,p=0.027),当其取值为67.58时,其预测3年DFS的敏感性为70.20％,特异性为64.30％;以67.58为界,PTR高于界值的患者预后较好(Log Rank=8.98,p=0.003),总生存时间明显长于低于界值的患者(35.63±17.61月vs 23.49±17.54月,Z=-2.80,p=0.005).结论 PTR对非转移性胃癌患者3年DFS预测存在一定价值,其中PTR较高的患者预后相对较好.

目的:分析海南部分地区(省内)与省外非转移性浸润性乳腺癌患者临床病理参数的异同.方法:收集我院自2012年6月-2017年6月经病理和影像学确诊的非转移性浸润性乳腺癌患者214例,筛选有效病例159例,将患者年龄、肿瘤位置、ScarffBloom and Richardson(SBR)分级、肿瘤标记物(CEA、CA125、CA153)、TNM分期、阳性/活检淋巴结数、lunima1分型、初潮年龄、绝经状态、生育子女数、体重指数、体表面积等数据按省内、省外进行统计分析.结果:①省内患者确诊年龄明显早于省外(47.48±10.05 vs 51.33± 10.03,p=0.02);②省内患者具有生育子女数较多(1.93± 0.97 vs 1.38± 0.64,p=0.00)和活检淋巴结数较多(20.67±9.56 vs 18.00± 6.74,p=0.04)的特征;③省内患者绝经后体重指数(22.66± 3.24 vs 25.56± 3.67,p=0.00)和体表面积(1.60± 0.12 vs1.68±0.16,p=0.00)较绝经前明显上升,而省外患者此现象不明显.结论:海南部分地区非转移性浸润性乳腺癌患者具有发病年龄早等特点,绝经后体质改变可能为该地区乳腺癌的促发因素.

目的:分析术前血脂(总胆固醇[Total cholesterol,TC]、甘油三酯[Triglyceride,TG]、高/低密度脂蛋白胆固醇[High/Low densitylipoprotein cholesterol,HDL-C/LDL])异常和乳腺癌患者临床病理参数的相关性.方法:根据纳入排除标准收集我院自2013年1月-2017年1月经病理证实的乳腺病病例共224例,其中浸润性乳腺癌88例(病例组),乳腺良性疾病136例(对照组),收集患者年龄、肿瘤位置、肿瘤细胞分化程度、肿瘤标记物(癌胚抗原、CA153、CA125)、TNM分期、肿瘤体积、阳性/活检淋巴结数、Luminal分型、初潮年龄、绝经状态、生育子女数、体重指数(BMI)、体表面积(BSA)等临床病理参数,同时收集术前1月内患者血脂检测结果进行统计分析.结果:①病例组术前TC值(p=0.02)、HDL-C/LDL值(p=0.04,p=0.00)与对照组相比差异具有统计学差异;②术前TC取值为4.62 mmol/L、TG取值为0.92 mmol/L、LDL取值为2.86 mmol/L时预测乳腺癌的灵敏度分别为54.5％、69.3％和61.6％,特异度分别为32.4％、45.9％和33％,曲线下面积分别为0.62(95％CI: 0.54-0.69,p=0.00)、0.64(95％CI:0.57-0.71,p=0.00)和0.64(95％CI:0.56-0.73,p=0.00);③以上述取值为分割点分析,在病例组中TG和LDL升高更多见于BMI(分别为:21.66±3.09 vs 25.11±3.37,p=0.00;22.99±3.70 vs 24.91± 3.48,p=0.03)偏高的患者,而TC和TG升高更多见于已绝经患者(分别为p=0.01;p=0.00)的患者.结论:乳腺癌患者术前存在一定程度血脂异常,该异常对协助诊断乳腺癌具有一定意义,术前BMI偏高和已绝经的患者存在TG和LDL值异常升高的可能性更大.

Chemoresistance is one of the most important causes of ovarian cancer‑related deaths. Recently, cancer stem cells (CSCs) have been recognized as the source of chemoresistance in ovarian cancer. However, the underlying mechanisms that regulate the chemoresistance of ovarian CSCs (OCSCs) remain unclear. The aim of the present study was to investigate the roles of S100B in the regulation of OCSC chemoresistance, which provides a novel therapeutic target. We observed high expression of S100B in CD133+ OCSCs derived from ovarian cancer cell lines and primary tumors and in cisplatin‑resistant patient samples. Then, we determined that S100B knockdown promoted the apoptosis of OCSCs after treatment with different concentrations of cisplatin. The underlying mechanism of S100B‑mediated chemoresistance in OCSCs may be through p53 inhibition. Furthermore, drug‑resistance genes, including MDR1 and MRP1, were involved in the process of S100B‑mediated OCSC chemoresistance. In conclusion, our results elucidated the importance of S100B in the maintenance of OCSC chemoresistance, which may provide a promising therapeutic target for ovarian cancer.

Gastric adenocarcinoma concurrent with metastatic neuroendocrine cancer (NEC) is rare. In the present case report, a 39-year-old male was first pathologically diagnosed by gastric endoscopy as having a highly differentiated adenocarcinoma. Next, positron emission tomography-computed tomography examination and bone marrow biopsy confirmed extensive metastasis. Subsequently, the patient underwent 6 cycles of immunotherapy (nivolumab, 160 mg) and 5 cycles of chemotherapy based on the XELOX regimen (oxaliplatin + capecitabine). Following this, the patient received the final cycles of nivolumab and XELOX; however, the patient then succumbed. Further biopsy of the metastatic collarbone lymph nodes indicated NEC. Overall, the progression-free survival was ~3.5 months, and overall survival (OS) was ~6 months. The case presented the possibility of concurrent gastric adenocarcinoma and NEC in the clinic. In addition, the efficacy of a combined regimen such as immunotherapy and chemotherapy for such disorders still requires further validation in the future.

结直肠癌在我国有很高的发病率和死亡率,T调节淋巴细胞是抗肿瘤免疫的关键一环.然而不同于其他实体肿瘤的研究结论,目前对于T调节淋巴细胞在结直肠癌中的意义,包括其在结直肠癌发生发展不同阶段的作用,在肿瘤组织内的不同部位、肿瘤组织与外周血、肿瘤不同区域引流淋巴结中的存在状态及对患者预后的影响等均存在不一致结论.临床上,针对PD-1/PDL-1和CTLA-4靶点免疫治疗的成功为以T调节淋巴细胞为着眼点的抗肿瘤研究提供了新方法,结合T调节淋巴细胞在结肠癌中的相关研究结论,未来在此领域仍有很大的探索空间.

Objective To evaluate the prognostic value of combined examination of pre-operative carcinoembryonic antigen (CEA) and CD44v6 for colorectal cancer patients. Methods A total of 140 patients with complete clinical data pathologically diagnosed as colorectal cancer from December 2012 to December 2017 in Hainan Hospital of PLA General Hospital were enrolled. Finally, 69 validated cases excluding CEA (-) or CD44v6(-) patients were registered according to pre-operative CEA detection and immunohistochemistry results of CD44v6. Kaplan-Meier method was used to analyze the progression-free survival (PFS) time for single factors. Multiple-factor analysis was done by using Cox proportional hazard model. Results Sixty-nine patients included 29 cases of double positive and 40 cases of double negative in CEA and CD44v6. There were statistical significances of the expressions of double positive and double negative in patients with different gender, M stage, TNM stage. Double positive was more apparent in female (χ2 = 4.42, P= 0.04), presenting of metastasis (χ2=5.06, P=0.02) and advanced cases (χ2=4.38, P= 0.04); univariable analysis showed the N stage (P=0.00), M stage (P=0.00), TNM stage (P=0.00) and double positive/double negative in CEA and CD44v6 (P= 0.04) were likely to affect the PFS, however, multivariable analysis showed that N stage (HR= 0.15, 95 ％ CI: 0.03-0.86, P= 0.03), TNM stage (HR= 23.83, 95 ％ CI: 3.65-155.51, P=0.00) were the independent prognostic factors for PFS. PFS in double positive patients was shorter than that in double negative ones [24.0 months (3-84) vs. 31.0 months (8-94), P=0.04]. Conclusion Pre-operative combined examination of CEA and CD44v6 could be helpful in judging the prognosis for colorectal cancer patients.

Natural killer (NK) cells recognize stress-activated NK group 2, member D (NKG2D) ligands in tumors. In the present study, the expression levels of NKG2D ligands were examined in four lung cancer cell lines (A549, PLA801D, NCI-H157 and NCI-H520). In the A549 cells, the expression of MHC class I polypeptiderelated sequence (MIC)A/B and UL16 binding protein (ULBP)1 was weak, the expression of ULBP2 was typical, and neither ULBP3 nor ULBP4 were expressed. The mechanism underlying the regulatory effect of a cancer treatment agent on the expression of NKG2D ligands was investigated using the proteasome inhibitor MG132. Following treatment for 8 h with MG132, the transcription levels of MICB and ULBP1 were upregulated 10.62- and 11.09-fold, respectively, and the expression levels of MICB and ULBP1 were increased by 68.18 and 23.65%, respectively. Notably, MICB exhibited significant time-dependent change. MG132 increased the transcription of MICB by acting at a site in the 480-bp MICB upstream promoter. The activity of the MICB promoter was upregulated 1.77-fold following treatment with MG132. MG132 treatment improved the cytotoxicity of NK cells, which was partially blocked by an antibody targeting NKG2D, and more specifically the MICB molecule. The expression of MICB induced by MG132 was inhibited by KU-55933 [ataxia telangiectasia mutated (ATM) kinase inhibitor], wortmannin (phosphoinositide 3 kinase inhibitor) and caffeine (ATM/ATM-Rad3-related inhibitor). The phosphorylation of checkpoint kinase 2 (Chk2), an event associated with DNA damage, was observed following treatment with MG132. These results indicated that MG132 selectively upregulates the expression of MICB in A549 cells, and increases the NKG2D-mediated cytotoxicity of NK cells. The regulatory effect of MG132 may be associated with the activation of Chk2, an event associated with DNA damage. The combination of MG132 with NK cell immunotherapy may have a synergistic effect that improves the therapeutic effect of lung cancer treatment.

In recent years,accumulating studies in cancer stem cells niche gradually opened an era of "niche time".As one of the classical solid tumors,colorectal cancer presented a relatively clear process of cancer initiating and development,which would be an ideal model for niche research.Paneth cells,which play a key role in supporting and protecting the intestine stem cells,are important element of normal intestinal epithelium and also one of the major components of the stem cells niche.However,the potential role of these cells,take the Paneth cells for example,on the road of colorectal epithelium malignant transformation are still largely unknown.Further studies aimed to uncover the relationship of Paneth cells with the intestine stem cells and its role in different stages of colorectal tumor development could expand the knowledge of cancer stem cells niche,also,could help to find the potential new therapeutic targets for colorectal cancer treatment in future.

OBJECTIVE Cyfra21-1 is one of the conventional tumor markers but its role in colorectal cancer are still largely unknown.The present study aimed to investigate the correlation between the value of preoperative Cyfra21-1 and the clinicopathological parameters in colorectal cancer patients.METHODS Totally 115 pathologically confirmed validated cases from June 1,2012 to 2016 were collected in our hospital,parameters including gender,age,tumor location,cancer cell differentiation,TNM stage,microsatellite state,Ki-67 index,risk factors and the value of Cyfra21-1,CEA were recorded and further statistical analysis were performed.RESULTS Positive rate of preoperative Cyfra21-1 and CEA was 38.26％(44/115) and 37.39％ (43/115),respectively.Double positive and only Cyfra21-1 positive rate was 19.13％(22/115),sole CEA positive rate was 18.26％ (21/115),whereas double negative rate was 43.47％ (50/115).Value of preoperative Cyfra21-1 presented significant statistical differences in different cancer cell differentiation (x2 =14.47,P＜0.001) and M stage (x2 =4.62,P-0.03),and preoperative CEA value shown similar differences in different T (x2 =17.72,P =0.00),M (x2 =7.81,P =0.00) and TNM stages (x2 =19.26,P＜0.001),both the max tumor diameter and number of positive lymph nodes were obviously elevated in Cyfra21-1 and CEA increased patients (all P＜0.05).Cancer cell differentiation was found to be the most significant factors that could affect Cyfra 21-1 by Logistic regression analysis (with respect to low differentiation,moderate OR:0.17,95 ％ CI:0.04-0.69,P =0.01;high OR:0.06,95 ％ CI:0.00-0.78,P=0.03).CONCLUSION Preoperative Cyfra21-1 has a relatively high positive rate in colorectal cancer patients and it would be helpful in estimating cancer cell differentiation and invasive range.

Objective To analyze the clinicopathological characteristics of patients with gastrointestinal malignant tumor in some parts of Hainan province and alien patients outside of Hainan province. Methods Three hundred and fifteen patients who were diagnosed by pathological confirmation were selected in Hainan Branch of PLA General Hospital from Jun 2012 to June 2016, clinicopathological parameters including age, gender, tumor location, cancer cell differentiation, body mass index (BMI), body surface area (BSA), value of preoperative tumor markers, TNM stages, microsatellite state, human epidermal growth factor receptor 2 (Her-2) staining, Ki-67 index and risk factors were collected and compared between local and alien patients. Results In contrast with patients outside of Hainan province, a significant lesser BMI [colorectal cancer: (23 ± 3) kg/m2 vs. (24 ± 4) kg/m2, t=-3.69, P< 0.05; gastric cancer: (21.50 ± 3.15) kg/m2 vs. (23.00 ± 3.61) kg/m2, t=-2.11, P=0.04] and BSA [colorectal cancer:[(1.73 ± 0.18) m2 vs. (1.82 ± 0.18) m2, t=-3.46, P<0.05;gastric cancer:(1.73 ± 0.16) m2 vs. (1.81 ± 0.18) m2, t=-2.09, P=0.04] were found in local patients. Local patients with colorectal cancer were much more younger [(57 ± 13) years old vs. (62 ± 13) years old, t=-2.30, P=0.02], with corresponding elevated positive rate of preoperative CEA (χ2=4.56, P= 0.03), T stages (χ2 = 8.31, P= 0.04) and TNM stages (χ2= 11.19, P= 0.01), however, no such difference was detected in gastric cancer patients (all P>0.05). Conclusions Patients with gastrointestinal cancer in some parts of Hainan province, in particular, colorectal cancer patients, present some exceptional clinicopathological features, which are marked by younger age at diagnosis, low level of BMI and BSA. In addition, preoperative level of CEA would be of important for these patients.

The treatment efficacy of advanced breast cancer is still not promising. This study aimed to compare the efficacy and safety of docetaxel/S-1 (DS1) versus docetaxel/capecitabine (DX) as the first-line treatment for advanced breast cancer.From June 2008 to June 2013, 22 patients with advanced breast cancer were treated with the DS1 regimen. Another 26 age- and disease status-matched patients treated with the DX regimen served as controls. The 2 groups were compared in terms of time to progression (TTP), objective response rate, disease control rate, clinical benefit rate, and safety profiles.Median TTP did not differ significantly between the DS1 group and the DX group (9.04 vs 10.94 months, P = 0.473). There were no significant differences in objective response rate, disease control rate, and clinical benefit rate between the 2 groups. Both the DS1 and the DX regimens showed good tolerability. The 2 regimens showed no significant difference in adverse events except degree III hand-foot syndrome (DS1 0 vs DX 23.1%, P = 0.025).For the first-line treatment of advanced breast cancer, the DS1 and the DX regimens showed similar efficacy and safety. The DS1 regimen had less severe hand-foot syndrome than the DX regimen.